• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FLOW trial stopped early due to evidence of renal protection with semaglutide.

作者信息

Gragnano Felice, De Sio Vincenzo, Calabrò Paolo

机构信息

Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Abramo Lincoln 5 - 81100 Caserta, Italy.

Division of Clinical Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Ferdinando Palasciano - 81100 Caserta, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):7-9. doi: 10.1093/ehjcvp/pvad080.

DOI:10.1093/ehjcvp/pvad080
PMID:37934595
Abstract
摘要

相似文献

1
FLOW trial stopped early due to evidence of renal protection with semaglutide.由于司美格鲁肽具有肾脏保护作用的证据，FLOW试验提前终止。
Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):7-9. doi: 10.1093/ehjcvp/pvad080.
2
Safety of Semaglutide.司美格鲁肽的安全性。
Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021.
3
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.司美格鲁肽：用于治疗成人 2 型糖尿病的药物评价及临床应用。
Can J Diabetes. 2019 Mar;43(2):136-145. doi: 10.1016/j.jcjd.2018.05.008. Epub 2018 Jun 5.
4
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.口服司美格鲁肽在伴有中度肾功能损害的 2 型糖尿病患者中的疗效和安全性（PIONEER 5）：一项安慰剂对照、随机、3a 期临床试验。
Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9.
5
Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?口服司美格鲁肽，首个可口服的胰高血糖素样肽-1 受体激动剂：它会是 2 型糖尿病的“灵丹妙药”吗？
Int J Mol Sci. 2021 Sep 14;22(18):9936. doi: 10.3390/ijms22189936.
6
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.在治疗 2 型糖尿病方面，每周一次皮下注射司美格鲁肽的疗效、安全性和心血管结局比较：来自 SUSTAIN 1-7 试验的结果。
Diabetes Metab. 2019 Oct;45(5):409-418. doi: 10.1016/j.diabet.2018.12.001. Epub 2019 Jan 4.
7
Clinical review of subcutaneous semaglutide for obesity.皮下司美格鲁肽治疗肥胖的临床综述。
J Clin Pharm Ther. 2022 Feb;47(2):184-193. doi: 10.1111/jcpt.13574. Epub 2021 Dec 28.
8
Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.司美格鲁肽对心血管风险连续谱中心血管事件风险的影响：SUSTAIN 和 PIONEER 试验的联合事后分析。
Cardiovasc Diabetol. 2020 Sep 30;19(1):156. doi: 10.1186/s12933-020-01106-4.
9
[The glucagon-like peptide-1 receptor-agonist semaglutide].胰高血糖素样肽-1受体激动剂司美格鲁肽
Ugeskr Laeger. 2019 Oct 7;181(41).
10
Semaglutide as a promising antiobesity drug.司美格鲁肽：一种有前途的抗肥胖药物。
Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb 15.

引用本文的文献

1
The multifaceted effects of semaglutide: exploring its broad therapeutic applications.司美格鲁肽的多方面作用：探索其广泛的治疗应用。
Future Sci OA. 2025 Dec;11(1):2483607. doi: 10.1080/20565623.2025.2483607. Epub 2025 Sep 3.
2
Association between the metabolic score for insulin resistance trajectory and new-onset metabolic syndrome: a retrospective cohort study based on health check-up data in China.胰岛素抵抗轨迹代谢评分与新发代谢综合征之间的关联：一项基于中国健康体检数据的回顾性队列研究
Lipids Health Dis. 2025 Aug 29;24(1):271. doi: 10.1186/s12944-025-02690-8.
3
Obesity-Related Kidney Disease: A Growing Threat to Renal Health.
肥胖相关性肾病：对肾脏健康日益增长的威胁。
Int J Mol Sci. 2025 Jul 10;26(14):6641. doi: 10.3390/ijms26146641.
4
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.综述文章：胰高血糖素样肽-1受体激动剂以及胰高血糖素/葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1受体双重或三重激动剂——非酒精性脂肪性肝炎的作用机制及新兴治疗前景
Aliment Pharmacol Ther. 2025 Jun;61(12):1872-1888. doi: 10.1111/apt.70196. Epub 2025 May 13.
5
GLP-1-based therapies for diabetes, obesity and beyond.基于胰高血糖素样肽-1（GLP-1）的糖尿病、肥胖症及其他疾病治疗方法。
Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8.
6
A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia.在深度镇静或全身麻醉前使用胰高血糖素样肽-1受体激动剂的叙述性综述。
J Anesth Analg Crit Care. 2025 Mar 28;5(1):16. doi: 10.1186/s44158-025-00237-y.
7
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment.司美格鲁肽作为一种胰高血糖素样肽-1（GLP-1）激动剂：肥胖治疗的一项突破。
Pharmaceuticals (Basel). 2025 Mar 12;18(3):399. doi: 10.3390/ph18030399.
8
The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.辅助药物在改善1型糖尿病治疗效果方面的前景：胰高血糖素样肽受体激动剂
J Diabetes Sci Technol. 2025 Mar;19(2):311-320. doi: 10.1177/19322968241309896. Epub 2024 Dec 31.
9
Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.降糖药物与2型糖尿病患者慢性肾脏病的一级预防：一项真实世界的基层医疗研究
Pharmaceuticals (Basel). 2024 Sep 29;17(10):1299. doi: 10.3390/ph17101299.
10
GLP1R Gene Expression and Kidney Disease Progression.GLP1R 基因表达与肾脏疾病进展。
JAMA Netw Open. 2024 Oct 1;7(10):e2440286. doi: 10.1001/jamanetworkopen.2024.40286.